Fulvestrant

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • PTPH1 confers breast cancer cell sensitivity to fulvestrant. E and F, PTPH1 overexpression increases the growth inhibition by fulvestrant. PTPH1 was overexpressed by a Tet-on system or a stable transfection, and resultant cells were incubated with fulvestrant as indicated for about 2 weeks. Colony formed was stained and counted. Results shown are normalized to its own solvent control of Vector and PTPH1-overexpressed cells, respectively (means ± SD; n = 3–5) with insets showing PTPH1 overexpression. *, versus vector or no Tet cells for E and F.

    Mol Cancer Ther 2014 13(1), 230-8. Fulvestrant purchased from Selleck.

    Biochim Biophys Acta, 2018, 1863(6):625-638. Fulvestrant purchased from Selleck.

  •  

    Fulvestrant resistance induced by 6 different ZF-TFs. (A) Drug sensitivity of fulvestrant-selected MCF7 ZF-TF-transduced cells. MCF7 cells transduced with one of six different ZF-TF-expressing retroviruses selected first in puromycin (the transduction selection marker) and then in fulvestrant for 1 month were grown in the absence of fulvestrant for 7 days and then challenged with 100 nM fulvestrant or vehicle (0.1% ethanol) for 21 days followed by crystal violet staining and visualization. Data are representative of triplicate experiments.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

    Fulvestrant resistance induced by 6 different ZF-TFs. (B and C) Growth curves of MCF7 and T47D cells in the presence and absence of fulvestrant. Comparison of cell growth rates (cell number, mean +/2 SEM, n = 8; time in days as indicated) of MCF7 and T47D cells stably transduced with control retrovirus or one of six different ZF-TF-expressing retroviruses (7, 19, 64, 70, 83 and 115) in the presence (blue line) or absence (pink line) of fulvestrant.

    PLoS One 2011 6, e21112. Fulvestrant purchased from Selleck.

  • CDK4/6 inhibitor resistance promotes diminished ER expression and activity. (a and b) Proliferation of MCF-7 and MR cells in the presence of different concentrations of ICI (a) or 4-hydroxytamoxifen (4-OHT) (b) was measured by the alamarBlue assay and plotted as % inhibition of proliferation against log concentration of inhibitor. Each data point represents the average value±s.d. of six replicates obtained in three independent experiments. (c) MCF-7 and MR cells were treated with different concentrations of ICI, collected after 24 h and then immunoblotted with the indicated antibodies.

    Oncogene, 2017, 36(16):2255-2264. Fulvestrant purchased from Selleck.

    A: Time dependent loss of MGMT activity in ERα-positive MCF7 and T47D tumor cells but not in ERα-negative MDAMB-468 cells after 1 μmol/L Fulvestrant treatment (upper panel). Concentration dependent inhibition of MGMT activity in MCF7 and T47D cells but not in MDA-MB-468 cells after a 72 hours exposure to fulvestrant (lower panel). The data represents the mean of two independent experiments in duplicate and the last time point (72 hours) as assessed by student's t-test was significant at P < 0.05. B: Decreased MGMT and ER-α protein levels in MCF7 cells after 48 hours and 72 hours fulvestrant exposure. ICI is fulvestrant, also called ICI-182,780. C: Decreased MGMT and ER-α protein levels in T47D cells after 48 hours and 72 hours fulvestrant exposure.

    J Biomed Res, 2016, 30(5):393-410. Fulvestrant purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NWTtN4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXKxMlMuOTByMDDuUS=> NVTPdXBZPDhiaB?= MmD5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYLyOos{OjR7N{myPVQ>
MCF-7/LTED MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjlUGYyNjNvMUCwNEBvVQ>? MX:0PEBp NHjVRYhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWm1RYJvOjR7N{myPVQ>
HCC1428 NGHhU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;mflB{OS5|LUGwNFAhdk1? NGLv[FY1QCCq MljnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2XwSlI1QTd7Mkm0
HCC1428/LTED NGTKO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjTR|EyNjNvMUCwNEBvVQ>? M4O4ZlQ5KGh? NYTXVFNFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXrhPZVWOjR7N{myPVQ>
LCC1 NVv5cWR2TnWwY4Tpc44hSXO|YYm= NGjX[lcyODBibl2= NETVNm41QC1zNESgbC=> NUXtOYlR[WO2aY\heIV{KFWSUjDzbYdv[Wyrbne= M2TVNlI1QDV6Mke3
LCC9 M3jHfmZ2dmO2aX;uJGF{e2G7 M2LSeVExOCCwTR?= MWW0PE0yPDRiaB?= NX;uR4JM[WO2aY\heIV{KFWSUjDzbYdv[Wyrbne= MVGyOFg2QDJ5Nx?=
MCF-7  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfMU5oyODBibl2= NEHO[JI2KGR? NHLtcXBqdmirYnn0d{Bk\WyuIHfyc5d1cCC2bzCxNQ+9jQ>? MYeyOFgyQTV3MB?=
mesangial  MnTESpVv[3Srb36gRZN{[Xl? NHXxdmYxNjFvMUCwJI5O NXjve5VJPDhiaB?= Mojid5VxeHKnc4Pld{BVT0ZvzsKxMYlv\HWlZXSgeJlx\SCLVjDjc4xt[Wenbh?= M{G2NVI1Pzl|NkO5
Mesangial M4jmbWZ2dmO2aX;uJGF{e2G7 MXuwMlEuOTByIH7N NXzaNY5POC53IHi= NUP6TllFcW6qaXLpeJMhXEeILd8yNU1qdmS3Y3XkJHNu[WR{IIDoc5NxcG:{eXzheIlwdiC4aXGgS3BGWg>? NVWxOYJiOjR5OUO2N|k>
ER+ MCF-7/2a M2LjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr2cFhTUUN3ME2wMlAxPCEQvF2= MXGxOVMzPDh6NB?=
ER+ MCF-7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLHNlAxKGh? MUnJR|UxRTBwMkGgcm0> Mne4NVU{OjR6OES=
MCF-7  NFm3RXhHfW6ldHnvckBCe3OjeR?= NW\mOYJCOTEEoH7NxsA> MonQO|IhcA>? M1fmUpJmfmW{c3XzJJRp\SCnc4Tyc4dmdiCnZn\lZ5QpUUN3MDCxMlkhy5diMUFijLI6KE1r NUHIZ2xIOjR7MEi2OVI>
MCF-7  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\6TWM2OMLib3[gZZBxem:6aX3heIVtgSB{IH7N MkP4NlM1PDh|NE[=
H1975  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHMN:Kh|ryP MUGxJI0> MojPbY5kemWjc3XzJJRp\SCpZX\peIlvcWJic3Xud4l1cX[rdImgc4YhUDF7N{WgZ4VtdHQEoB?= M37CZlI1OjZ6OEGw
H1975 NEXTdFBHfW6ldHnvckBCe3OjeR?= M4nGU|PDqM7:TR?= Mmm2NUBu MU\1dJJm\3WuYYTld{B1cGVibHX2[Ywhd2ZiTHX0MVdk NIjNR5UzPDJ4OEixNC=>
MCF-7  MYjGeY5kfGmxbjDBd5NigQ>? NVix[|VnOTBy4pEJcm3DqA>? MUK3NkBp MoDCdoV3\XK|ZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1KG:oIFWyxsBqdiClZXzsJIlvfmG|aX;u Mk[1NlM6OzZ5N{O=
MCF-7  MVTGeY5kfGmxbjDBd5NigQ>? M2HYRVExOOLCiX7NxsA> NYPCcZZvOjRxNEigbC=> NW\B[5Zi\mGlaXzpeIF1\XNiaX72ZZNqd25idHjyc5VocCCPTWDzK{Bud2S3bHH0bY9v NYnNS2xvOjN7M{[3O|M>
BT474-tet-shMED1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rmZVAvOS13IN88US=> MYK3JIQ> MVvpcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NILkRmgzOzl|NkKzOC=>
ZR75-1-tet-shMED1  MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3RNE4yNTVizszN MV23JIQ> MoXRbY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYeyN|k{PjJ|NB?=
MCF-7-tet-shMED1 NUC4SW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMlEuPSEQvF2= NHTXOWE4KGR? MVfpcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn3uNlM6OzZ{M{S=
HepG2  NWTMUWNwTnWwY4Tpc44hSXO|YYm= Moe2NE4xOS1zMDFOwG0> NFz1V48yQCCqwrC= MUPhZ5RqfmG2ZYOgeIhmKEWURT3t[YRq[XSnZDD0doFve2O{aYD0bY9vKG:oIFHGNmVT NGHHWHkzOzd|M{G4PC=>
MCF-7L  NIjOb3BHfW6ldHnvckBCe3OjeR?= NEHySpYyODBibl5CpC=> NELUc4YyOCCvaX6vNlQhcC92ODDo M1SyXpJme3WudIOgbY4hTUeIUjygTGVTOiCjbnSgTGVTOyCyaH;zdIhwenmuYYTpc44h[XRicILvcI9v\2WmIHX4dI9{fXKn MWSyN|Y5PjRzNh?=
MCF-7L  MmPJSpVv[3Srb36gRZN{[Xl? M2DZPVExOCCwTdMg NES3clY1QCCq M3LnO4lv\HWlZYOgeZBz\We3bHH0bY9vKG:oIH3SUmEhd2ZiRVfGVkBtcWejbnSgTGIuTUeI M1u5RlI{Pjh4NEG2
MCF-7L M1q1b2Z2dmO2aX;uJGF{e2G7 Mlf4NVAxKG6PwrC= NYjCbpNwPDhiaB?= MXXpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT NVfhR2w2OjN4OE[0NVY>
C4-12  NWPjNmJVTnWwY4Tpc44hSXO|YYm= MorCNVAxKG6PwrC= NUnIVY9rPDhiaB?= MXLpcoR2[2W|IFXHSnIh\mGvaXz5JI1mdWKncjDhZ5RqfmG2aX;uJJJmeXWrcnXkJGVT NETZe4kzOzZ6NkSxOi=>
MCF-7L NWDlTlM5TnWwY4Tpc44hSXO|YYm= NF;zdI4yODBibl5CpC=> M13BbFI1KGh? NIHOUJNqdmS3Y3XzJGVITlJicHjvd5Bpd3K7bHH0bY9vKHKncYXpdoVlKEiELVXHSkBnfW6ldHnvci=> M1KyTlI{Pjh4NEG2
MMQ  NGfoZXhHfW6ldHnvckBCe3OjeR?= NXv1ZoxGOC14MkWgcm0> M2nHdFczKGh? NIfTc5Nld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDld5Rzd2enbjDy[YNmeHSxcj5OtUApTVMQsTm= NVv6T5h{OjN3MkOzOVc>
H1975  NVvlfnZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHWNE4{OTJ3LUGwJO69VQ>? MoTzOkBl NEXlcmhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnyyNlM{QTl7NUe=
H1975  NFrD[odCeG:ydH;zbZMhSXO|YYm= NG\HcokzODBibl2= MkC5O|IhcA>? NIK0b|JmdmijbnPld{BmemyxdHnubYIhcW6mdXPl[EBieG:ydH;zbZM> NVXPUmJtOjN|OUm5OVc>
MCF-7  MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXZNVAwOTByL{GwNFAhdk1? MXKyM|QwPiCm MVXEUXNQ MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ M3v4c|I{OzF|NUC2
MCF-7  NVPvW3BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnWNVAxKG6P NWXaXVA2PCCm NWj1ZWN{TE2VTx?= NUnmd4lqcW6mdXPld{BiKGirZ3jldkBxem:yb4L0bY9vKG:oIHPlcIx{KGmwIITo[UBIOSCyaHHz[eKh NXvZNnZ7OjN|MUO1NFY>
MLO-Y4  MlHHSpVv[3Srb36gRZN{[Xl? NVPDVopjOcLizszN NXv2TI1EOSCq M{jEbIlvcGmkaYTzJGUzNWmwZIXj[YQhS3h2MzDlfJBz\XO|aX;u M4r5WVI{OjR5MEW3
MCF-7 NX\XVVJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f2UVExOCCwTR?= NXPVSmdKPDhiaB?= NHSw[lli[nKxZ3H0[ZMhfGinIIDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKG2xZHXyZZRmKG6rdILvd4F1cX[nIIP0doV{ew>? NHTO[|czOzJzNke0OC=>
TG1-1  MWDGeY5kfGmxbjDBd5NigQ>? Mli4NeKh|ryP NVrDSXpKOjRiaB?= MnvwZYJzd2ejdHXzJGUzyqCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBJUUZvMd8x NYHHdVUyOjNyOEi2NFc>
TG1-1  NFTxWmNHfW6ldHnvckBCe3OjeR?= NX7LNYRCOcLizszN Mnu4NlQhcA>? M1nZbYFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhWEl|Sx?= MXqyN|A5QDZyNx?=
MCF7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLvdnViOTByIH7N NUPtcIJKPDhiaB?= M2W0R4xm[WS|IITvJIEhe2mvaXzhdkBtd3O|IHnuJJN2en[rdnHsJIF{KHerdHig[I95d3K3YnnjbY4h[WyxbnW= NIW1elYzOzB5N{K0PS=>
MCF7 NEnMbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j3b|ExOCCwTR?= M4LONVQ5KGh? NHHPS|hmdmijbnPld{BvfXSuaX6tcYVlcWG2ZXSgZ4VtdCCmZXH0bC=> NVj6Vnk1OjNyN{eyOFk>
MCF-7  MlfQSpVv[3Srb36gRZN{[Xl? NI\EUms3KGh? NYjWeYpMTE2VTx?= NIeyUXVifHSnboXheIV{KHSqZTDmcJVlcW:6b37pcE0hd3JiZnXubIV5[W2rZD3pcoR2[2WmIHnuZ5Jm[XOnIHnuJI1qWi1{MTDlfJBz\XO|aX;u MkPNNlMxPTJyM{[=
MCF-7 NYHUTm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jXZVExOCCwTT:xJO69VQ>? MmnROUBl NFHtbJJqdmirYnn0d{B1cGVic4TpcZVt[XSrb36gc4YhOTgQsj3ld5Rz[WSrb3y= MmrVNlI6QDJ5NkW=
MCF-7 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S4VFExOCCwTR?= Mk\3OUBl MWHpcohq[mm2czD0bIUhe3SrbYXsZZRqd25ib3[g[pV{[XKrZXzpckBJ NUHhWZpuOjJ7OEK3OlU>
1471.1 M2nFTmZ2dmO2aX;uJGF{e2G7 MlzUNVAxKG6P MmLENUBp M1XS[2V1V0kEoB?= Mnv4eIFs\XNib36gZUBxfW6ldHH0[UB{fGGrbnnu[{Bx[XS2ZYLu MXGyNlg3QTFyNh?=
MCF-7 MkftSpVv[3Srb36gRZN{[Xl? MXOxNFAhdk1? MlHrNUBp MYnFeG9JyqB? NFjPfmd1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> Mmn3NlI5PjlzME[=
HeLa NXHrb5lPTnWwY4Tpc44hSXO|YYm= NFvUZYsyODBibl2= NX;DRYFVOSCq NF3lV5NGfE:KwrC= MXz0ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= MXyyNlg3QTFyNh?=
COS-7  M2jPemZ2dmO2aX;uJGF{e2G7 NGS0Z20yODBibl2= M3jCUVEhcA>? MXnFeG9JyqB? NIXnUIp1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> NHXqPWEzOjh4OUGwOi=>
BG1L-OHTLT  MXPGeY5kfGmxbjDBd5NigQ>? NHrmS3UyOMLibl2= MYOyOOKhcMLi NIqzS4xqdmirYnn0d{BGWs7zIHX4dJJme3Orb36= MUKyNlY2OjV3OB?=
BG1L-ICILT NFjUeppHfW6ldHnvckBCe3OjeR?= M4DqfFExyqCwTR?= MkPnNlTDqGkEoB?= M2S5dIlvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= M{LZSFIzPjV{NUW4
PC-9 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHwSWUxNjByMz2zNEDPxE1? NWfERYRuPDhiaB?= MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmfZNlI2PjB4M{S=
H1650 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6wMlAxOy1|MDFOwG0> M37yR|Q5KGh? M2CxTYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIPUWlMzOjV4ME[zOC=>
H1975 NGfRS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSwMlAxOy1|MDFOwG0> NF:3[oo1QCCq MlvIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUCyNlU3ODZ|NB?=
H1975 NHrifolHfW6ldHnvckBCe3OjeR?= M4jPelPDqM7:TR?= MWmzJIg> NEO3T4Fi[nKxZ3H0[ZMhfGinIIDoc5NxcG9vRVfGVkBqdmS3Y4Tpc44h[nliZYP0do9o\W5? NUO4[np1OjJ3NkC2N|Q>
H1975 MnfpSpVv[3Srb36gRZN{[Xl? M3LrcVPDqM7:TR?= MoTpO{Bl NFKwdoJqdmS3Y3XzJGVITlJiZYjwdoV{e2mxbh?= M{DXOlIzPTZyNkO0
HTR-8 MX;GeY5kfGmxbjDBd5NigQ>? MmDLNeKh|ryP NUP2fG5EOS12ODDo M1Hv[4Rwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFnHSmJRPyCvUl7B NHn1VmczOjN6M{GxNS=>
JEG-3 MVfGeY5kfGmxbjDBd5NigQ>? MVWxxsDPxE1? MVqxMVQ5KGh? NH3iXm5ld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDJS2ZDWDdibWLORS=> MYGyNlM5OzFzMR?=
Huh7 MlXySpVv[3Srb36gRZN{[Xl? MXO1NOKh|ryP NIrVem81QCCq MlfCbY5pcWKrdIOg[4VvcXO2ZXnuMY1m\GmjdHXkJHBQVjFidILhcpNi[3SrdnH0bY9v MlfDNlI{ODR{OU[=
201T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ocpB1PSEQvF2= MWG3NkBp NWSxNmFXcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= M4jubVIzOjV6NEe2
A549  NYjHWpA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XIWlUh|ryP MkDGO|IhcA>? NYDwUWhFcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= MVmyNlI2QDR5Nh?=
MCF-7 M37TZmZ2dmO2aX;uJGF{e2G7 MX2xxsDPxE1? MVmyOEBpyqB? MUTkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb36gbY5lfWOnZDDifUA1NU:KLWSgxsA> NUH4[YdiOjJyNEmzNVY>
HCC-1428 Ml;ISpVv[3Srb36gRZN{[Xl? MYKxxsDPxE1? NIDWW|IzPCCqwrC= NHHEO3Nld3ewcnXneYxifGW|IFXSJIV5eHKnc4Ppc44hcW6mdXPl[EBjgSB2LV;IMXQhyqB? NEPuOZUzOjB2OUOxOi=>
MDA-361 MnXQSpVv[3Srb36gRZN{[Xl? NXraO5ZTOcLizszN NGfKe28zPCCqwrC= NVfUcHVH\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NFvmU5ozOjB2OUOxOi=>
ZR75-1 MXvGeY5kfGmxbjDBd5NigQ>? Ml7ENeKh|ryP NXT6VGV5OjRiaNMg MkTU[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uJIlv\HWlZXSgZpkhPC2RSD3UJOKh NYjLRYRsOjJyNEmzNVY>
MCF-7 NG\KVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDzNeKh|ryP NIrL[lI2NTFyIHS= MXLzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> MojMNlIxPDl|MU[=
HCC-1428 M3HHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nzW|HDqM7:TR?= MXy1MVExKGR? MXTzeZBxemW|c3XzJGUzNWmwZIXj[YQh\3Kxd4ToJIlvcGmkaYTpc44> MX6yNlA1QTNzNh?=
MDA-361 M4DH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOxxsDPxE1? MnnsOU0yOCCm NIjJZ3l{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? M2ewXlIzODR7M{G2
ZR75-1 M{Lw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXXd5NJOcLizszN M1izeFUuOTBiZB?= NWTCe2tWe3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w NIexVoIzOjB2OUOxOi=>
MCF-7/AC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XlVlAuOC5{IN88US=> Mnz1OkBl NFG0eGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCvb3Tld5RtgQ>? M3LCXFIzODR{N{my
MCF7 M{\LbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWwO25MOTBiwsXN NUnHOYlEPDhiaB?= NV3QZo1zcW6mdXPld{Bk\WyuIHnubIljcXSrb36ge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IH\pZpJw[myjc4Tz M4DUe|IzODRzOEi3
MMQ NXzTOndIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG2c4tlOC14MkWgcm0> MUG3NkBp NF70S41xem:mdXPld{B{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70JIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wwrC= M3XBUFIzODF3MUCx
MMQ NX7oVVM5TnWwY4Tpc44hSXO|YYm= NEnvRZkxNTZ{NTDuUS=> MXu3NkBp MnTCdJJw\HWlZYOgZUB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70MEBld3OnLXTldIVv\GWwdDDy[YR2[3Srb36gbY4hWFKOIIPlZ5JmfGmxbh?= MlzlNlIxOTVzMEG=
MCF7 M{HBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH0NE0yKM7:TR?= Mly4NlQuOTJyIHi= MmP2bY5pcWKrdIOgeIhmKGe{b4f0bEBw\iCPQ1[3MXlDNTIEoB?= NF;qZWgzOTh4M{K1PC=>
HepG2 MVHBdI9xfG:|aYOgRZN{[Xl? MnnqNE4yyqEQvF2= MYmyOEBp M{\mO4Fjd2yrc3jld{B1cGViZYP0do9o\W5vaX7keYNm\CC3cD3y[Yd2dGG2aX;uJI9nKGGyb1HJJIFv\CCjcH;N MXOyNVgyPjJ|Mx?=
MCF7–iFR3 NFjNU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn0dG0zOC1zMECgcm0> NELBToI6PiCq NXm5[29p\W6qYX7j[ZMhSVBvaX7keYNm\CClZXzsJIdzd3e2aDDpcohq[mm2aX;u NXmyVFl{OjF5OUK4PFk>
MCF7S MmPBSpVv[3Srb36gRZN{[Xl? MU[xxsDPxE1? NHHBR3U1QCCq MlLt[I94dnKnZ4XsZZRmeyCxdnXyZYxtKEWUzsGgdJJwfGWrbjDs[ZZmdHN? NU\KO4E2OjF3M{OxPVU>
MCF7 NWLMeFZVTnWwY4Tpc44hSXO|YYm= NIrR[nEyyqEQvF2= MVm0PEBp M2DCc4Rwf26{ZXf1cIF1\XNib4\ldoFtdCCHUt8xJJBzd3SnaX6gcIV3\Wy| NVO2UlEyOjF3M{OxPVU>
MCF7S NYDnRnp3TnWwY4Tpc44hSXO|YYm= NIrrN4IyyqEQvF2= M2S3blch\A>? MoDtZZR1\W63YYTld{B1fW2xcoPwbIVz\SCob4LtZZRqd25iYX7kJJBzd2yrZnXyZZRqd25? M1jST|IyPTN|MUm1
MCF7S MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHLTHcxNjVxMTFOwG0> MkK4O{Bl NFyxUm9FVVOR NH[0emNl\WO{ZXHz[ZMh[2WubDDlfJBidnOrb36= NV3a[HZYOjF3M{OxPVU>
T47D  NVjmZ3RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCOEBvVQ>? NUKxSHRUPDBiaB?= NFqxfIV{fXCycnXzd4V{KGOnbHyg[5Jwf3SqIH3v[IVz[XSnbIm= NV;vdo02OjF2OECzPVE>
BT474  NEn1UJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDtSow1KG6P NIrORYQ1OCCq MUjzeZBxemW|c3XzJINmdGxiZ4Lve5RpKG2xZHXyZZRmdHl? MUOyNVQ5ODN7MR?=
T47D  NWXBRlFuTnWwY4Tpc44hSXO|YYm= NULHbHFsOTBibl2= NUfJTVRmPDBiaB?= MlvS[I94dnKnZ4XsZZRmeyCHUt8xJJBzd3SnaX6= NWfFZY9kOjF2OECzPVE>
BT474  NFHBTWhHfW6ldHnvckBCe3OjeR?= Mme2NVAhdk1? M4r2S|QxKGh? NEDoZnpld3ewcnXneYxifGW|IFXS{tEheHKxdHXpci=> NYHsWnhKOjF2OECzPVE>
MCF7 NGDudmxHfW6ldHnvckBCe3OjeR?= MV6xNFAhdk1? M2TTWlch\A>? NXuwc3BjemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? MV[yNVM6PjB7NB?=
T47D  MnzQSpVv[3Srb36gRZN{[Xl? M1LDeVExOCCwTR?= M{fQN|ch\A>? Mn:xdoVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NGThN5gzOTN7NkC5OC=>
BT474  MWLGeY5kfGmxbjDBd5NigQ>? NEi0OnkyODBibl2= M33j[lch\A>? MnrrdoVlfWOnczDFVu6yKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NU\tO2N{OjF|OU[wPVQ>
MDAMB361 M1fnTGZ2dmO2aX;uJGF{e2G7 NIDUbIYyODBibl2= MmPpO{Bl NIS0Uopz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 MoHiNlE{QTZyOUS=
MCF7 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zDRVAvODFvMTFOwG0> MVW3JIQ> MYDy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? Mlm2NlE{QTZyOUS=
T47D  M1jpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3WNE4xOS1zIN88US=> M2XQNVch\A>? M4PxfJJm\HWlZYOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= M4PhNFIyOzl4MEm0
BT474  NYOwR2k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;INE4xOS1zIN88US=> MnK0O{Bl M2PhW5Jm\HWlZYOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NHzLb3YzOTN7NkC5OC=>
MDAMB361 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2wMlAyNTFizszN NGfpUZE4KGR? MVvy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? MViyNVM6PjB7NB?=
MCF7 NHvCTYVHfW6ldHnvckBCe3OjeR?= MUOxNFAhdk1? NGf6d2c4KGR? NWfCO2xXcW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> NWe0XYZ2OjF|OU[wPVQ>
T47D  NXXy[I45TnWwY4Tpc44hSXO|YYm= NUDGTHQ4OTByIH7N NGnmdGg4KGR? MonSbY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= MYKyNVM6PjB7NB?=
BT474  M2DFVWZ2dmO2aX;uJGF{e2G7 M3nhUVExOCCwTR?= NXjzSnBYPyCm MofabY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= Mo\pNlE{QTZyOUS=
MDAMB361 MlnSSpVv[3Srb36gRZN{[Xl? MoH2NVAxKG6P NUjZZlA3PyCm NIDxTpRqdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n M3[3Z|IyOzl4MEm0
MCF7 NHf4UGNHfW6ldHnvckBCe3OjeR?= NEHG[HEyOCCwTR?= NGj2eYc6PiCq M4rYSIRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvcuKh MUeyNVM4QDN|Mx?=
MDA-MB-231 NGna[WNHfW6ldHnvckBCe3OjeR?= Mne3NVAhdk1? NFHFdlc6PiCq Mn3q[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> M1O1WlIyOzd6M{Oz
SK-BR-3 M4q1N2Z2dmO2aX;uJGF{e2G7 MX6xNEBvVQ>? NVTaS2txQTZiaB?= MoT2[I94dnKnZ4XsZZRmeyCHUjDlfJBz\XO|aX;uxsA> MVyyNVM4QDN|Mx?=
MCF-7 NWLNTmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCxNFAhdk1? M3;GOlczNzl4IHi= NYWyfmtM[2G3c3XzJINmdGxiY4njcIUh[XK{ZYP0 NIKzfmEzOTJ7OUi2Ni=>
MMQ NUnhXIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHmfmxyOC5yMEitOlI2KG6P MUK3NkBp MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml7kNlA4ODB5NUW=
MMQ NWnOcIw1TnWwY4Tpc44hSXO|YYm= MWGwMlAxQC14MkWgcm0> MY[3NkBp MlTZbY5pcWKrdIOgVHJNKHOnY4LleIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGXvc|czODdyMEe1OS=>
MMQ MYjGeY5kfGmxbjDBd5NigQ>? MVGwMlA1NTZ{NTDuUS=> MVq3NkBp MU\pcohq[mm2czDFVu6yKGW6cILld5Nqd25? NGTnTZgzODdyMEe1OS=>
MMQ MYHGeY5kfGmxbjDBd5NigQ>? NXnzb4JvOC5yND22NlUhdk1? NFPaUJo4OiCq NFT1WGl2eHKnZ4XsZZRmeyCWR1dOtlMh[W6mIGTHSu6zWkmLIHX4dJJme3Orb36= M{XM[FIxPzByN{W1

... Click to View More Cell Line Experimental Data

In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Formulation: 50 mg/mL in arachis oil
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Ethanol 100 mg/mL warmed (164.8 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
0.4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
in solvent
Synonyms ICI-182780, ZD 9238

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03691493 Not yet recruiting Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Bone|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8 Emory University|Pfizer December 1 2018 Phase 2
NCT03554044 Not yet recruiting Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma University of California San Francisco|Amgen December 11 2018 Phase 1
NCT03531645 Not yet recruiting Malignant Neoplasms of Female Genital Organs M.D. Anderson Cancer Center|AstraZeneca|Pfizer November 2018 Phase 2
NCT03685331 Not yet recruiting Metastatic Breast Cancer|Locally Advanced Breast Cancer|Advanced Breast Cancer|BRCA2 Mutation|BRCA1 Mutation Abramson Cancer Center of the University of Pennsylvania September 2018 Phase 1
NCT03584009 Recruiting Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer Hoffmann-La Roche September 13 2018 Phase 2
NCT03643510 Recruiting Adenocarcinoma of Endometrium Memorial Sloan Kettering Cancer Center|Eli Lilly and Company August 21 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products3

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID